Drug dosing during pregnancy—opportunities for physiologically based pharmacokinetic models
- 26 June 2020
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 47 (4) , 319-340
Abstract
Drugs can have harmful effects on the embryo or the fetus at any point during pregnancy. Not all the damaging effects of intrauterine exposure to drugs are obvious at birth, some may only manifest later in life. Thus, drugs should be prescribed in pregnancy only if the expected benefit to the mother is thought to be greater than the risk to the fetus. Dosing of drugs during pregnancy is often empirically determined and based upon evidence from studies of non-pregnant subjects, which may lead to suboptimal dosing, particularly during the third trimester. This review collates examples of drugs with known recommendations for dose adjustment during pregnancy, in addition to providing an example of the potential use of PBPK models in dose adjustment recommendation during pregnancy within the context of drug-drug interactions. For many drugs, such as antidepressants and antiretroviral drugs, dose adjustment has been recommended based on pharmacokinetic studies demonstrating a reduction in drug concentrations. However, there is relatively limited (and sometimes inconsistent) information regarding the clinical impact of these pharmacokinetic changes during pregnancy and the effect of subsequent dose adjustments. Examples of using pregnancy PBPK models to predict feto-maternal drug exposures and their applications to facilitate and guide dose assessment throughout gestation are discussed.Keywords
This publication has 175 references indexed in Scilit:
- Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and PostpartumJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Effect of pregnancy on emtricitabine pharmacokineticsHIV Medicine, 2011
- Prescription drug use during pregnancy in developed countries: a systematic reviewPharmacoepidemiology and Drug Safety, 2011
- Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimensJournal of Antimicrobial Chemotherapy, 2011
- Pharmacokinetics of oseltamivir among pregnant and nonpregnant womenAmerican Journal of Obstetrics and Gynecology, 2011
- Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Pharmacokinetics of Metformin during PregnancyDrug Metabolism and Disposition, 2010
- Clonidine Pharmacokinetics in PregnancyDrug Metabolism and Disposition, 2009
- Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis for Better Clinical PracticeClinical Pharmacology & Therapeutics, 2009
- Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsHIV Medicine, 2008